chrisvoncsefalvay/vaers-outcomes huggingface dataset:
cannot get up to answer the door; This is a spontaneous report from a contactable consumer or other non hcp (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient stated, " the workers were supposed to come today and give me my second shot today nobody showed up, yet they were supposed to be here at 1230 supposed to be here before my nurse go home because I cannot get up to answer the door." A nurse was supposed to come to the residence to give second dose to caller and had not shown up yet. Indicated called number on the paper. "I did not have that what was on the card, they put it in the mail. Gave it to me on the street. Ya would be giving out the shots, they supposed to be late, and the medicine is already messing people up." So, who do I get in contact with to let them know they were supposed to. The clinical outcome of the event was unknown. The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Patient collapsed following the vaccine. She was caught by MA and placed into a chair. She started convulsing for roughly 30 seconds to 1 minute then was placed onto the floor on her side. Convulsions stopped and supplemental oxygen was applied. We were advised by 911 dispatch to administer epinephrine. This was done in left thigh. EMTs arrived. Patient was evaluated and advised by EMTs that they were clear to go home.
Abdominal cramps and fever 101F on 11/17/09. Fever increased to 103F 11/18/09 am. Mother of client took child to ER 11/18 and was released same day w/ instructions of TYLENOL / MOTRIN use + "Brat Diet".
Patient swelled up severely very soon after the Johnson and Johnson Covid 19 vaccine....She passed away approximately 3 weeks after the 2nd vaccine.
skin reaction at site of injection;  red, swollen, hot, itchy; size appr 4 in x 2.5 in, oval reaction started 7 days after injection and took 2 weeks to clear
Her body was hurting for 2 days and then it stopped; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 26Feb2021 15:00 (Lot number: EN6201) at the age of 78 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Diabetes" (unspecified if ongoing); "pain" (unspecified if ongoing). Concomitant medication(s) included: HYDROCODONE taken for pain, start date: 2017 (ongoing); JANUVIA [SITAGLIPTIN] taken for diabetes mellitus (ongoing). Vaccination history included: Bnt162b2 (Lot: EN5318.She thinks it was administered in her left arm.), administration date: 02Feb2021, when the patient was 78 years old, for COVID-19 immunisation. The following information was reported: PAIN (non-serious) with onset 26Feb2021, outcome "recovered" (28Feb2021), described as "Her body was hurting for 2 days and then it stopped".  Additional Information: No additional vaccines was administered on same date of BNT162B2. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The event did not result to Physician Office and Emergency Room Visit .  No follow-up attempts are possible. No further information is expected.
clustered migraine on one side of head, fogginess and forgetfulness, muscle aches, pressure similar to muscle ache or muscle sprain near chest area.
Patient experienced an anaphylactoid reaction within 20 mins of receiving the vaccine. Patient is a physician and attempted to self treat with diphenhydramine. After a short time of seemingly no resolution patient presented to the Emergency Department. Patient was examined. Elevated BP was noted (192/100), flushing, difficulty swallowing, and strange sensation of mouth and tongue were also present. An ECG was preformed and sinus tachycardia was observed at 105bpm. Patient received IM epinephrine and PO dexamethasone. Symptoms resolved. Patient was observed for 3-4 more hours.
Severe cramps, moodiness and Menstruated more frequently (was on a 28 day cycle prior to vaccination): 3/17/21 6 days, 4/4/21 6 days, 4/17/21 6 days, 5/2/21 still bleeding.   Long term effects still unknown!!
Headache, Myalgia, Arthralgia,  INJECTION SITE PAIN Narrative:
Warm spot at the injection site; Sore spot at the injection site; Itchy spot at the injection site; looked like a rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Warm spot at the injection site), VACCINATION SITE PAIN (Sore spot at the injection site), VACCINATION SITE PRURITUS (Itchy spot at the injection site) and VACCINATION SITE RASH (looked like a rash at the injection site) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011D21A) for COVID-19 vaccination.     No Medical History information was reported.  On 20-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (Warm spot at the injection site), VACCINATION SITE PAIN (Sore spot at the injection site), VACCINATION SITE PRURITUS (Itchy spot at the injection site) and VACCINATION SITE RASH (looked like a rash at the injection site). At the time of the report, VACCINATION SITE WARMTH (Warm spot at the injection site), VACCINATION SITE PAIN (Sore spot at the injection site), VACCINATION SITE PRURITUS (Itchy spot at the injection site) and VACCINATION SITE RASH (looked like a rash at the injection site) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   No relevant concomitant medications was reported. Treatment information was not provided.    This case was linked to MOD-2021-372658 (Patient Link).
32 y/o AD WM TSGT reports dx of GBS "less than 30 days s/p 2nd AVA" (AVA #2 06/12/2003; Typhoid SC 02/19/2003 per DEERS) and a dx of MS in April of 2004 contacts ASK VHC: "My neurologist insinuated all this could be vaccine related."  Symptoms: Weakness, Gait abnormality, Fatigue, Malaise <60 Days, Diarrhea.  9/19/08 Medical records reviewed.  Pt received Anthrax #1, on 4/7/2003, Bioport, Lot# FAV 071; & typhoid injection #2, on 2/19/2003, AP, Lot # U1073.  No Lot # recorded for Anthrax #2.  Records reveal patient experienced GBS 6/30/2003;followed by MS 4/1/2004, optic neuritis 4/2004.
onset of breathing difficulties, tightening in chest and heaviness in chest about 3 weeks after my 2nd booster shot.
Patient complained of persistent coughing, difficulty in breathing, throat tightness since last evening. Came to the hospital today treated with Benadryl and albuterol nebulizer treatment. Transferred via 911 to downtown hospital ER.
Pain in L shoulder with limited ROM, started after injections, slightly improved but never fully resolved and continues to have difficulty with flexion and abduction above 90 degrees with aching pain
Discharge Provider: MD Primary Care Provider: MD Admission Date: 8/15/2022 Discharge Date: Aug 18, 2022  PRESENTING PROBLEM: Cellulitis of left lower extremity [L03.116] COVID-19 [U07.1] Cellulitis [L03.90]   HOSPITAL COURSE: Patient is a 49-year-old woman with a past medical history significant for developmental delay who presented to the emergency department with concern for bilateral lower extremity cellulitis.  Was found to have a positive COVID-19 PCR.  Slowly became hypoxic requiring up to 4 L during her hospitalization.  Initially was given 1 dose of IV Decadron and started on oral Decadron and remdesivir.  Hypoxia quickly resolved and patient was not having any respiratory symptoms.  Decadron and remdesivir were discontinued.  Patient was treated with IV cefazolin for bilateral lower extremity cellulitis which improved during hospitalization.  Subsequently discharged on oral Decadron to complete 10 days of total therapy.  Patient was discharged in medically stable condition.
01/18/2008 moderate Other Had 100-101 fever, reported that arm felt sore and had a lump on her lymph gland, went to her
On 3/5 @ 10pm, the patient experienced fatigue and sore throat On 3/6, she experienced muscle aches in the calves and sore throat. She also produced green mucus. She developed a low grade fever temp 100 F for which she took Tylenol. She also had night sweats. The symptoms have resolved since then and her COVID test was negative.
Resident got Moderna Booster 0.25ml, however she had the booster on 6/9/22 and on 12/2/21, making this her 3rd Booster
A 73 yr old female was found sitting in the observation area after receiving her first Covid 19 vaccine (Pfizer). Pt began to have a ?fuzzy? feeling and feeling of dissociation from her body. The pt got the attention of EMS and a wheel chair was brought over to her to bring her the private exam room. Pt remained in wheel chair and vs were taken. Initial bp was 168/102, hr was 97, spo2 was 97% ra. Pt states she has anxiety and feels she may have had a panic attack. Pt rested for 10 mins and had a drink of water. Pt vs were Retaken and improved. Pt pub was 153/104, hr was 85, resp  18, spo2 was 97% ra. Pt signed a form that she accepted treatment but refused transport. Pt was released back to observation area and proceeded to check out.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 76-year-old female patient who received SHINGRIX (batch number 4492P, expiry date 25th April 2020). On 18th April 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 19th April 2018, 1 days after receiving SHINGRIX, the patient experienced injection site erythema and injection site swelling. On an unknown date, the outcome of the injection site erythema and injection site swelling were unknown. The reporter considered the injection site erythema and injection site swelling to be almost certainly related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in the left deltoid and experienced redness and swelling at the injection site. The patient went to her doctor and got a prescription.
She just has a feeling of not feeling too well; fever; sore throat; her ears and face feels like a sinus issue; feeling of ear and face having a "sinus issue"; headache; This is a spontaneous report from a contactable consumer.     A 40 years old female patient received bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: FA7484; Expiration Date: unknown), dose 1 via an unspecified route of administration, administered in Arm Left on 30Jul2021 09:30 (at the age of 40 years) as dose 1, 0.3 ml single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient did not receive any other vaccination 4 weeks prior to COVID-19 vaccination. On 30Jul2021 10:00, the patient experienced headache; 03Aug2021, the patient experienced sore throat, her ears and face feel like a sinus issue (at 07:00), fever (at 14:00), feeling of ear and face having a "sinus issue"; on an unspecified date, the patient experienced she just has a feeling of not feeling too well. The clinical outcome of the events headache, feeling of ear and face having a "sinus issue", her ears and face feels like a sinus issue was not resolved; sore throat was resolving; fever, was resolved on 04Aug2021; She just has a feeling of not feeling too well was unknown.  No follow-up attempts are possible. No information is required.
Case symptom onset 8/4/21 which included runny nose and headache. Wife was a positive case.
Woke up with fever the next day (May 3) was treated with ADVIL, right thigh was red and swollen. Noticed a rash on her bottom that went up her back to her neck (red with little white dots, was rough to the touch). By Saturday May 7th her nose was looking infected with pus in the cut, her face was red and swollen. Went to the ER, MD was more concerned about the infected nose than the rash. Treated with Amoxicillin. Seemed to get better, but by the 14th or 15h she became covered from head to toe with a red rash and had fever. This morning May 17th, went to PMD, who treated her with antihistamine and a steroid, thought it might be a reaction to the antibiotic. She will follow up with the patient in a few days.
Sore arm at injection site beginning 4 hours after shot. Nausea, weakness, dizziness beginning 20 hours after injection. Fatigue, fever and chills beginning 22 hours after injection. Sore arm lasted about 4 days, all other symptoms subsided within about 24 hours from their onset.
Pt presented to ER w/ hisotry of 2 short episodes of apnea < 10sec. Overnight observation revealed no abnormalities.
Was taken to pharmacy for Janssen Covid-19 shot, she passed away after hospitalization for bilateral blood clots in lungs and blood clout in leg. Date of death July 31, 2021.  (Cause of death per death certificate:  pulmonary thromboembolism and deep venous thrombosis.)
headache /waking up in the morning with a headache / headaches that come and go; low grade fever / highest fever/ with a reading of 101.2 F; This case was reported by a consumer via call center representative and described the occurrence of fever in a 59-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th September 2020, the patient received the 1st dose of Shingrix (intramuscular) 50 µg. On 10th September 2020, less than a day after receiving Shingrix, the patient experienced headache. In September 2020, the patient experienced fever. On an unknown date, the outcome of the fever was recovered/resolved and the outcome of the headache was not recovered/not resolved.   It was unknown if the reporter considered the fever and headache to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving the vaccine the patient developed a headache that day. The patient developed headache was not severe the first few days and occurred in the evenings towards 10 pm when going to bed. The patient reported waking up in the morning with a headache once in a while.  The patient reported still experiencing headaches that come and go and that they now occur throughout the day. For relief he may use Tylenol, Aspirin or Advil. If headache is minor, consumer reports not using a pain reliever. Headaches have not resolved. Around 14th or 15th September 2020, The patient reported developing a low grade fever, and recorded taking temperature on the 15th September 2020 at 9:45 PM and having a low-grade fever. The patient reported the highest fever was 17th September 2020 at 6:50 PM with a reading of 101.2 F. The patient reports ever since then that temperature recordings have been below 98.6 F. Fever reportedly resolved. The reporter consent to follow up.
This is a spontaneous report from a contactable consumer. A patient of unspecified age and gender received TRUMENBA via an unspecified route of administration on an unspecified date at a single dose for immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced headache and sensitivity to light in eyes. Outcome of the events was unknown. Information on batch and lot numbers has been requested.
This spontaneous report as received from a pharmacist refers to a 70 year old male patient. The patient had no pertinent medical history and concomitant medications. On 13-SEP-2016, the patient was inadvertently vaccinated with ZOSTAVAX lot # L036823 intramuscularly into the deltoid muscle. On 13-SEP-2016, the patient deltoid muscle had a muscle spasm. On 13-SEP-2016, the muscle spasm resolved in an unspecified amount of time with no medical intervention of treatment. No lab tests had been performed. The reporter did not provide the causality between the event and the suspect therapy. Additional information has been requested.
10 days after administration, patient reported tenderness and induration at injection site. Painful upon touch, and 1cm circumferential soft tissue swelling and hardening still to this day.
Very large 6 inch diameter area of erythema with warmth/tenderness where DTaP/IPV arm.
Blurry vision in right eye; Pressure behind and around the eye; headaches; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 44 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 21Jan2022 14:00 (Batch/Lot number: unknown) at the age of 44 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose 1, single, Lot No: Er8736, administered in Arm Left on 21Apr2021 at 11:00 AM), administration date: 21Apr2021, when the patient was 43 years old, for Covid-19 immunization; Bnt162b2 (Dose 2, single, Lot No: Fw0182, administered in Arm Left on 12May2021 at 01:00 PM), administration date: 12May2021, when the patient was 43 years old, for Covid-19 immunization. The following information was reported: VISION BLURRED (hospitalization, disability) with onset 23Jan2022 13:00, outcome "not recovered", described as "Blurry vision in right eye"; OCULAR DISCOMFORT (hospitalization, disability) with onset 23Jan2022 13:00, outcome "not recovered", described as "Pressure behind and around the eye"; HEADACHE (hospitalization, disability) with onset 23Jan2022 13:00, outcome "not recovered", described as "headaches". The patient was hospitalized for vision blurred, ocular discomfort, headache (start date: 2022, discharge date: 2022, hospitalization duration: 3 day(s)). The events "blurry vision in right eye", "pressure behind and around the eye" and "headaches" were evaluated at the physician office visit and emergency room visit. Therapeutic measures were taken as a result of vision blurred, ocular discomfort, headache which included steroids. The patient experienced blurry vision in right eye pressure behind and around the eye leads to headaches. It has been 2 months and have no improvement. This has been horrible. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.  The lot number for bnt162b2 was not provided and will be requested during follow up.
shingles; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013620A) for COVID-19 vaccination.     No medical history was reported.     On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, the patient experienced HERPES ZOSTER (shingles). At the time of the report, HERPES ZOSTER (shingles) outcome was unknown. Not applicable      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter. Treatment Shingles medications The patient had the second dose scheduled on 14-Feb-2021. A week prior of the administration of the second dose, the patient  developed shingles and received shingles medications as a treatment. The vaccination provider told her to not receive the vaccine until the medication was over.
I am experiencing aches and pains throughout my body; My joints are clicking; This is a spontaneous report from a contactable consumer or other non hcp (patient himself).   A 45-years-old male patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Lot number: FE3181, Expiry date: Unknown, Age at vaccination: 45 years) via an unspecified route of administration, administered in Arm Left on 26Aug2021 as dose 1, singe for COVID-19 immunisation. The patient's medical history and concomitant medications were none. The patient had no known allergies. The patient was not tested positive for COVID-19 prior to vaccination and had not been tested post vaccination. Patient did not receive any other vaccines within 4 weeks prior and other medications 2 weeks prior to the COVID vaccine. On 26Aug2021, the patinet stated that, immediately after receiving the vaccine and through today, I am experiencing aches and pains throughout my body. My joints are clicking. I never had this before. It is interfering with my routine and life. I did not want to take the vaccine. I did so because of a workplace mandate. I got a call from human resources. Tylenol and Aleve don't help. I am concerned that the vaccine triggered an autoimmune reaction. No treatment taken for the events. The outcome of the events was unknown.
100.5 fever/chills, body aches. Treated with ibuprofen. Resolved within 24hrs of vaccine.
Scattered excoriated papular-vesicular lesions, legs, abdomen, chest; 1.5cm round collection of vesicles beneath right knee, lat and larger patch above and to side.
Had DTAP/IVP in left deltoid on 08/09/2005.  Developed 11x10cm area of erythema, tenderness at site.
dizzy, severe arm pain, swollen arm, swollen under breast/underarm, skin ultra sensitive, arm numbness, ear ringing, 99F to 100F fever over 24 hour period, extreme fatigue, extreme chills. I felt so terrible and in pain, I wished someone would just take me out, unbearable sickness, fatigue, pains, and chills for 3 days.  Despite I moved my arm around lots after the shot, drinking lots of fluids including Gatorade, and ate good meals.  This was merely my COVID Booster (3rd shot), as I thought it would be a smaller dose; and this is my worst reaction of the 3 shots I've received.  I'm still recovering from this shot on my 3rd day, hopefully all will be well, but this was beyond painful.
Experienced nausea again; This case was reported by a consumer via call center representative and described the occurrence of nausea in a 16-year-old female patient who received Flu Seasonal QIV  (FluLaval Quadrivalent 2021-2022 season) (batch number 292R2, expiry date unknown) for prophylaxis.   Co-suspect products included flu seasonal qiv  pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   The patient's past medical history included nausea (it went away for a week prior to receiving Flulaval).   On 25th January 2022, the patient received FluLaval Quadrivalent 2021-2022 season and Flulaval Tetra Pre-Filled Syringe Device. On 25th January 2022, less than a day after receiving FluLaval Quadrivalent 2021-2022 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced nausea. On an unknown date, the outcome of the nausea was not recovered/not resolved.   It was unknown if the reporter considered the nausea to be related to FluLaval Quadrivalent 2021-2022 season and Flulaval Tetra Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: This case was reported by the patient's parent. The patient received dose of FluLaval Quadrivalent vaccine and experienced nausea. The nausea was ongoing. The reporter did not have the expiration date. The reporter consented to follow up via email only and requested that subject line say something that will reference the AE.